Health TrialsbyHealthPanel

Antagonism of Neostigmine in Continuous Infusion of Mivacurium

ConditionNeuromuscular Blocking Agents
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBeijing Tongren Hospital

About this trial

In this study, the antagonism of neostigmine, a cholinesterase inhibitor, on continuous infusion of mivacurium during foot and ankle surgery under general anesthesia was investigated, and the appropriate time point of antagonism was explored.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

18 - 65 years old;

American Society of Anesthesiologists (ASA) physical stastus classification system: I-II;

Body mass index (BMI) 18.5 - 30 kg/m2

Patients with normal cholinesterase levels before the operation

Disqualifiers

Refusal to participate in the study;

ASA classification of grade III or above;

Severe organ dysfunction, difficult airway or neurological muscle disorders;

Taking drugs that affect neuromuscular monitoring or neuromuscular conduction function;

Trial design

Design model

Parallel

Treatments tested in this trial

  • Neostigmine

    Drug

    Administer neostigmine at a dose of 0.04 mg/kg (combined with 0.02 mg/kg atropine)

Treatment groups

120 Participants
are divided into 3 treatment groups
Group A: Non-antagonistic groupNo intervention 0 interventions
Group B: Count-2 antagonist groupExperimental treatment 1 intervention
Group C: Train of four stimulation ratio (TOFr) 0.4 antagonist groupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

The time from count 2 to TOFr recovery to 0.9

Time frame
Perioperative

Secondary outcomes

1

The time from count 2 to TOFr recovery to 0.7

Time frame
Perioperative
2

The time from count 2 to TOFr recovery to 0.4

Time frame
Perioperative
3

Mean Arterial Pressure

Time frame
Perioperative
4

Blood pressure

Time frame
Perioperative

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Beijing Tongren Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: